Physician profile
Eonjung Kim
NPI 1306307905
$1,119.68
in general payments reported to CMS, 2019-2025
16 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $456.26 | 2025 | |
| Pfizer INC. | $182.76 | 2025 | |
| Eisai INC. | $90.59 | 2025 | |
| Tanabe Pharma America, INC. | $45.66 | 2025 | Radicava |
| Novartis Pharmaceuticals Corporation | $45.45 | 2025 | |
| Neurelis, INC. | $43.29 | 2025 | Valtoco |
| Inspire Medical Systems, INC. | $42.41 | 2025 | Inspire |
| Sk Life Science, INC. | $31.56 | 2025 | |
| Vanda Pharmaceuticals INC. | $29.71 | 2025 | Ponvory |
| Amneal Pharmaceuticals LLC | $27.67 | 2025 | Crexont |
| Lundbeck LLC | $27.26 | 2025 | Vyepti |
| Acadia Pharmaceuticals INC | $25.54 | 2025 | Nuplazid |
| Csl Behring | $20.20 | 2025 | Hizentra |
| Catalyst Pharmaceuticals, INC. | $18.48 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $17.03 | 2025 | Ajovy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $15.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eonjung Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.